Hepatic Toxicity after Acebutolol Therapy
Authors: L. Ann Tanner
Journal: Annals of Internal Medicine (1989)

Brief Reports15 September 1989Hepatic Toxicity after Acebutolol TherapyL. Ann Tanner, BS, RPh, L.A. Bosco, MD, MPH, Hyman J. Zimmerman, MDL. Ann Tanner, BS, RPhSearch for more papers by this author, L.A. Bosco, MD, MPHSearch for more papers by this author, Hyman J. Zimmerman, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-6-533 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptElevated serum transaminase and alkaline phosphatase levels have occurred in association with most of the beta-adrenoreceptor blocking agents (1). These reactions, however, have not been reported in the literature. Although two groups from West Germany (2-4) reported pathologic findings consistent with hepatitis in association with propranolol, these cases were confounded by other compounds associated with hepatic injury. Liver toxicity has not been previously reported with acebutolol (Sectral; Wyeth-Ayerst Laboratories, Philadelphia, Pennsylvania), a cardioselective adrenoreceptor blocking agent with intrinsic sympathomimetic activity. We report a possible association between exposure to acebutolol and liver toxicity.Case ReportsSince 1985 the Division of Epidemiology...References1. Physician's Desk Reference. 42nd ed. Oradell, New Jersey: Medical Economics Co, Inc; 1988. Google Scholar2. KunzePorstTschopel KHL. Morphology and pathogenesis of liver injury produced by dihydralazine, propranolol and ketophenylbutazone. Zentralbl Allg Pathol. 1985;130:509-18. MedlineGoogle Scholar3. KunzePorstLohmannTschopel KHJL. Liver lesions induced by dihydralazine and propranolol. Zentralbl Allg Pathol. 1985;130:19-29. MedlineGoogle Scholar4. ReinhardtMachnikKrombholzJahn MGBG. The so-called dihydralazine hepatitis. A contribution to the pathogenesis. Dtsch Z Verdau Stoffwechselkr. 1985;45:283-94. MedlineGoogle Scholar5. . National Prescription Audit. Ambler, Pennsylvania; 1988. Google Scholar6. BerkowFletcher RA, eds. The Merck Manual of Diagnosis and Therapy. 15th ed. Rahway, New Jersey: Merck Sharp & Dohme; 1987:2412. Google Scholar7. Zimmerman H. Hepatotoxicity. New York: Appleton-Century-Crofts; 1978:349-69. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: L. Ann Tanner, BS, RPh; L.A. Bosco, MD, MPH; Hyman J. Zimmerman, MDAffiliations: From the Division of Epidemiology and Surveillance, Office of Epidemiology and Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrugs and ToxinsAcebutololHepatotoxicity of Cardiovascular and Antidiabetic DrugsHepatic injury due to drugs, herbal compounds, chemicals and toxinsLiver Disease Caused by DrugsAtenolol Hepatotoxicity: Report of a Complicated CaseDrugs Used to Treat Hypertension, Heart Failure, and Angina PectorisDrug-induced liver injury: Is it somehow foreseeable?AcebutololHepatotoxityHypersensitivity Immune Reaction as a Mechanism for Dilevalol-Associated Hepatitisβ-adrenoceptor antagonists and antianginal drugs 15 September 1989Volume 111, Issue 6Page: 533-534KeywordsBiostatisticsDrug administrationDrug research and developmentDrugsEpidemiologyFood and Drug AdministrationHepatitisLiverPhosphatasesToxicity ePublished: 1 December 2008 Issue Published: 15 September 1989 PDF downloadLoading ...